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Merkel Cell Carcinoma

Cynthia L. Bartus, M.D., Steven A. Oberlender, M.D., Ph.D., and Christian W. Oram, D.O.
Lehigh Valley Health Network, Allentown, Pennsylvania and Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania

Case Presentation:

Discussion:

Patient: H.K. is a 97 year-old Caucasian female.
History of Present Illness: Patient presented from a personal care facility with a one month history of a
rapidly enlarging and fungating mass on the left cheek. Excisional biopsy was performed and a diagnosis of Merkel
cell carcinoma was established. After extensive family counseling, wide local excision was agreed upon as a course
of action. On the day of the proposed surgery (within one month of the initial diagnosis) the lesion had recurred
to the original size. On physical exam she was found to have pre-auricular, sub-mental, and anterior cervical
lymphadenopathy. She also had a mild wound infection at the biopsy site. With the patient in poor health, and the
possibility of local metastatic disease, the family elected hospice care.
Medical History: Dementia, dysphagia, hypothyroidism, congestive heart failure, type II diabetes, chronic kidney
disease, chronic obstructive pulmonary disease
Family History: Unknown
Current Medications: Lorazepam, levothyroxine, fentanyl, acetaminophen, cephalexin/doxycycline (for wound
infection)
Physical Examination: 2.3 x 1.5 x 1.2 cm hemorrhagic crusted exophytic tumor on the left cheek.
Biopsy: CBL Path (D12NY1-0414557, 12/28/2012) Left cheek: “Ulcerated dense multinodular dermal/subcuticular
infiltrate of large poorly differentiated basaloid epithelial cells with ‘salt and pepper’ chromatin and high n:c ratios.
Abundant mitotic activity is present. With immunostains, the lesional cells stain in a characteristic fashion with CK20,
CK7 (rare), neurofilament, chromogranin, and synaptophysin (patchy and mild), and do not stain with TTF-1, LCA, or
S100.”
Reason for Presentation: Interest
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Figure 1A: December
2012: Hemorrhagic crusted
exophytic tumor on the left
cheek.
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Figure 1B: January 2013:
Four weeks s/p excisional
biopsy showing recurrence.
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Figure 2A: H&E
December 2012: Infiltrating
dermal nodule.
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Figure 2B: H&E December
2012: Infiltrating cords of
basaloid cells.
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Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. Originally described by
Toker in 1972, the exact origin of Merkel cells is still a matter of debate, with some hypothesizing an origin from
neural crest stem-cells. At presentation, 66% of patients have local disease, 27% have nodal involvement, and 7%
have distant metastases. The reported incidence has more than tripled over the last 20 years, with some authors
contributing this increase to improved detection by the immunohistochemical marker cytokeratin-20 (CK20). Known
risk factors include T-cell suppression and extensive prior sun exposure. This link to immune suppression led to the
discovery of the Merkel cell polyomavirus (MCPyV) in 2008.
Current thought, through several experimental observations, suggests that tumor growth is dependent on
contribution of the MCPyV and independent immune system involvement. MCPyV is incorporated into host DNA
causing an integration mutation. A truncation mutation follows, eliminating viral replication, and allows persistent
oncogenic function. Persistent viral antigen expression inactivates the retinoblastoma tumor suppressor protein
allowing tumor growth. Independently, MCPyV evades the immune system by UV-mediated immune tolerance,
chronic antigen exposure, downregulation of antigen expression, and immunosuppressive cytokines. The other
critical tumor suppressor pathway that is altered in the course of tumor progression is p53. It is also believed that
the MCPyV can inactivate the AKT-mTOR signaling pathway, thus promoting tumor growth.
Immune response is currently being studied as a prognostic indicator. The presence of MCPyV antibodies appears to
correlate with tumor burden in MCC patients. High antibody titers, (>10,000), appears to result in better progressionfree survival than low titers. High intratumoral infiltration of CD8+ cells may confer increased survival, compared
to sparse or no infiltration. In the future, vaccination against MCPyV, or modification and enhancement of the host
immune response, offers a promising role in the treatment of MCC.
Currently, there are no consensus guidelines for staging. (18)F-fluorodeoxyglucose positron emission tomography in
conjunction with high resolution CT scan appears to offer the most accurate staging of disease. Surgery remains the
mainstay of treatment with either wide local excision or treatment with Mohs surgery to ensure complete removal.
Patients who are able to undergo sentinel lymph node biopsy are encouraged to do so. Radiation and chemotherapy
may be used as adjuvant therapy.
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Figure 2C: H&E December
2012: Sheets of small
basophilic cells in the dermis
with vesicular nuclei.
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Figure 2D: H&E December
2012: Vascular invasion of
tumor cells.
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Figure 2E: December
2012: Positive perinuclear dot
CK20 staining.

Figure 2F: December
2012: Chromogranin positive
cells.
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